Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acura’s Phase III pain drug study meets end point
The Phase III study (study 105) was a randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of Acurox tablets for relief of moderate to severe pain
The Phase III study (study 105) was a randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of Acurox tablets for relief of moderate to severe pain
The Testosterone replacement in hypogonadal men with either metabolic syndrome or Type 2 diabetes study looked at the effects of Tostran on insulin resistance, diabetic control, lipids, quality
In this single blinded study seven Type 2 diabetic subjects were dosed with AKP-020 and two with placebo for 28 days. Over the 28-day period, both placebo subjects
Pharmacokinetic analysis revealed that 131I-TM601 rapidly clears from the blood stream and is then quickly removed from the body through the urinary system. Additionally, imaging localization analysis showed
In the 18-month trial, bapineuzumab appeared to have clinical activity in treating Alzheimer’s disease. The study did not attain statistical significance on the primary efficacy endpoints in the
The study conducted by the US National Cancer Institute is a seven-arm, Phase II, open-label trial of romidepsin in patients with cutaneous T-cell lymphoma (CTCL) and peripheral T-cell
For European oncologists who prescribe 5-fluorouracil (5-FU) continuous infusion regimens alone or in combination (eg Folfox and Folfiri) for colorectal, stomach, breast, and pancreatic cancers, this simple, evidence-based
Ron Creeley, vice president of marketing and sales at Simulations Plus, said: “This is our first software license from the Environmental Protection Agency (EPA). We’re especially pleased that
Rapydan, a medicated plaster, is manufactured by Eusa Pharma. The easy-to-use plaster works by combining two local anesthetic agents (lidocaine and tetracaine) with a breakthrough controlled heat-assisted drug
The panel’s recommendation will be considered by the FDA during completion of its review of the premarket approval for ProGEL. The panel’s recommendation for FDA approval was conditioned